[ad_1]
Senator Wyden’s proposal is far from the success of today’s and the future’s urgent healthcare needs
This Partnership against Chronic Disease (PFCD) Today, the following statement was issued on the principles for recent reforms proposed by the Chairman of the Senate Finance Committee Ron Wyden (D-OR):
“We agree that reducing the cost of prescription drugs for patients is an important goal. Although the chairman’s statement is aimed at proposing a consensus proposal that can pass both houses of Congress, these principles and subsequent statements closed the door to bipartisan efforts and opened up the lack of it. More radical changes supported by the two parties and houses.
Six out of ten Americans have at least one chronic disease, and four out of ten Americans have two or more chronic diseases. People covered by health insurance and black and brown Americans are disproportionately affected by chronic diseases. These individuals and their families need treatment that can help best manage their medical needs, as well as reliable medical insurance to better prevent these diseases. Out-of-pocket expenses and coverage restrictions (including failure priority policies) severely restrict access, but Senator Wyden’s principles have largely failed to address these issues. For millions of people with chronic diseases, treatments are limited or non-existent, so accelerated innovation is essential. These principles can have a profound impact on medical innovation and delay or eliminate relief for millions of people whose medical needs are not met.
Senator Wyden’s principles call for increased government intervention, which will weaken the resources required for innovative research and development and harm patients, leading to fewer new drugs developed in the next decade.
Removal of protective measures that prohibit government pricing, namely non-interference clauses, will open the door to restrictions on access to medical insurance. Because of the Congressional budget…
The full story on Benzinga.com
[ad_2]
Source link
